Adjuvant immunotherapies are substances that are either used alone, or in combination with other immunotherapies, to boost the immune response even more.
Adjuvant immunotherapies hope to improve responses to cancer vaccines that use T-cells or other immune cells.
How do adjuvant immunotherapies work?
Some adjuvant immunotherapies use 'ligands' to boost immune responses. Ligands are molecules that can bind to protein receptors on cells, with names such as 'toll-like receptors (TLRs)'. These are molecules that are used to boost the body's immune response. They have shown some effectiveness in brain, kidney, lung, colon, pancreatic, prostate, ovarian and breast cancer.
Checkpoint inhibitors come under this broad category.
If you have further questions, need to clarify any of the information on this page, or want to find out more about research and clinical trials, please contact our team:
Information and Support line
0808 800 0004 (free from landlines and mobiles)
Phone lines open Mon-Fri, 09:00-17:00
Research & Clinical Trials Information
You can also join our active online community on Facebook - find out more about our groups.